Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19

Authors:

Abstract
No abstract available
Funding Information
  • Pfizer

This publication has 30 references indexed in Scilit: